Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenetic Biosciences (XBIO) Equity Average (2023 - 2025)

Xenetic Biosciences' Equity Average history spans 6 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Equity Average fell 12.97% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, down 12.97%, while the annual FY2025 figure was $6.7 million, 15.19% down from the prior year.
  • Equity Average reached $5.7 million in Q4 2025 per XBIO's latest filing, up from $4.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $13.4 million in Q1 2023 to a low of $4.2 million in Q3 2025.
  • Average Equity Average over 3 years is $8.2 million, with a median of $7.7 million recorded in 2024.
  • The largest YoY upside for Equity Average was 12.97% in 2025 against a maximum downside of 41.95% in 2025.
  • A 3-year view of Equity Average shows it stood at $10.3 million in 2023, then tumbled by 36.95% to $6.5 million in 2024, then fell by 12.97% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Equity Average are $5.7 million (Q4 2025), $4.2 million (Q3 2025), and $4.8 million (Q2 2025).